文献速递胸部肿瘤

Sigvotatug Vedotin(IB6靶向ADC)在晚期非小细胞肺癌剂量扩展的首次人体I期研究

First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2026-04-20

SGNB6A-001是一项开放标签、多中心、剂量递增/扩展的I期研究,在晚期NSCLC患者中评估Sigvotatug vedotin(SV)的安全性与抗肿瘤活性。剂量扩展阶段探索了三种方案,共治疗117例患者。总体客观缓解率19%,中位缓解持续时间11.3个月;非鳞癌且未接受过紫杉烷治疗患者分别为29%和12.8个月。药代动力学与临床数据支持推荐1.8 mg/kg调整理想体重每2周一次方案进一步研究。

要点

  • SV在晚期NSCLC中安全性可控,任何级别和≥3级TEAE发生率分别为98%和48%。
  • 1.8 mg/kg AiBW每2周方案PK变异性低于总体重方案。
  • 总体ORR 19%,非鳞癌未接受紫杉烷患者ORR 29%。

核心结论

  • SV在晚期NSCLC中显示出可控的安全性和有前景的抗肿瘤活性,缓解持久。
  • 药代动力学和临床数据支持推荐1.8 mg/kg AiBW每2周一次方案进一步研究。

研究设计与样本

  • SGNB6A-001为开放标签、多中心、剂量递增/扩展的I期研究,评估安全性、耐受性、药代动力学和抗肿瘤活性。
  • 剂量扩展阶段探索三种方案:1.25 mg/kg TBW第1、8天(21天周期),1.5 mg/kg TBW第1、15天(28天周期,每2周一次),1.8 mg/kg AiBW每2周一次。
  • 截至2024年11月26日,共117例晚期NSCLC患者在上述队列中接受治疗。

主要发现

  • 所有患者任何级别和≥3级治疗中出现的不良事件发生率分别为98%和48%。
  • 接受1.8 mg/kg AiBW每2周一次的患者任何级别和≥3级TEAE发生率分别为94%和35%。
  • 模型显示AiBW方案药代动力学变异性低于TBW方案。
  • 总体人群客观缓解率为19%,中位缓解持续时间为11.3个月。
  • 非鳞癌且未接受过紫杉烷治疗患者的客观缓解率为29%,中位缓解持续时间为12.8个月。

临床怎么用

  • SV在晚期NSCLC中安全性可控,推荐1.8 mg/kg AiBW每2周一次方案进一步研究。
  • 非鳞癌且未接受紫杉烷治疗患者可能从SV获得更高缓解率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Integrin beta-6 (IB6) is highly expressed in non-small cell lung cancer (NSCLC) and other solid tumors and potentially associated with poor outcomes. Sigvotatug vedotin (SV), a novel IB6-directed antibody-drug conjugate, demonstrated acceptable safety and encouraging antitumor activity in dose escalation. We report updated results for dose-expansion regimens in advanced NSCLC (aNSCLC). METHODS: SGNB6A-001 is an open-label, multicenter, dose-escalation/dose-expansion phase I study evaluating safety, tolerability, pharmacokinetics (PK), and antitumor activity of SV in patients with select advanced solid tumors. After dose escalation, dose expansion further explored three regimens: 1.25 mg/kg total body weight (TBW) on Days 1 and 8 of a 21-day cycle, 1.5 mg/kg TBW on Days 1 and 15 of a 28-day cycle (once every 2 weeks), and 1.8 mg/kg adjusted ideal body weight (AiBW) once every 2 weeks. Eligible patients had prior chemotherapy and immunotherapy or targeted therapy if indicated. Primary end points were safety and determination of an optimal dosing schedule. Secondary end points were antitumor activity, PK, and immunogenicity. RESULTS: As of November 26, 2024, 117 patients with aNSCLC were treated in the above cohorts. Any-grade and grade ≥3 treatment-emergent adverse events occurred in 98% and 48% of all patients, respectively, and in 94% and 35% of patients receiving SV 1.8 mg/kg AiBW once every 2 weeks. Modeling revealed that the AiBW regimen resulted in lower PK variability than TBW regimens. The objective response rate and median duration of response were 19% and 11.3 months in the overall population, respectively, and 29% and 12.8 months in patients with nonsquamous, taxane-naïve NSCLC. CONCLUSION: SV demonstrated a manageable safety profile and promising antitumor activity with durable responses in aNSCLC. PK and clinical data support further investigation with the recommended 1.8-mg/kg AiBW once every 2 weeks dosing regimen.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Peters S, Piha-Paul SA, Sehgal K, et al. First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. J Clin Oncol. 2026. PMID: 42008777. doi:10.1200/JCO-25-02016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。